Yang-Xin Fu

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 31

Top Topics

Toll Like Receptor

Helicobacter Pylori

Dendritic Cells

Immune Response

Top Venues

Nature communications

Science translational medicine

Science immunology

Cellular & molecular immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Chuanhui Han, Victoria Godfrey, Zhida Liu, Yanfei Han, Longchao Liu, Hua Peng, Ralph R Weichselbaum, Hasan Zaki, Yang-Xin Fu
The AIM2 and NLRP3 inflammasomes trigger IL-1-mediated antitumor effects during radiation. Science immunology 6 (59) (2022)
Gui-Zhen Wang, Li Zhang, Xin-Chun Zhao, San-Hui Gao, Li-Wei Qu, Hong Yu, Wen-Feng Fang, Yong-Chun Zhou, Fan Liang, Chen Zhang, Yun-Chao Huang, Zhihua Liu, Yang-Xin Fu, Guang-Biao Zhou
Author Correction: The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nature communications 13 (1) (2022)
Young Min Son, In Su Cheon, Yue Wu, Chaofan Li, Zheng Wang, Xiaochen Gao, Yao Chen, Yoshimasa Takahashi, Yang-Xin Fu, Alexander L Dent, Mark H Kaplan, Justin James Taylor, Weiguo Cui, Jie Sun
Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses. Science immunology 6 (55) (2022)
Yuzhu Hou, Hua Laura Liang, Xinshuang Yu, Zhida Liu, Xuezhi Cao, Enyu Rao, Xiaona Huang, Liangliang Wang, Lei Li, Jason Bugno, Yanbin Fu, Steven J Chmura, Wenjun Wu, Sean Z Luo, Wenxin Zheng, Ainhoa Arina, Jessica M S Jutzy, Anne R McCall, Everett E Vokes, Sean P Pitroda, Yang-Xin Fu, Ralph R Weichselbaum
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Science translational medicine 13 (582) (2021)
Daria Beshnova, Jianfeng Ye, Oreoluwa Onabolu, Benjamin Moon, Wenxin Zheng, Yang-Xin Fu, James Brugarolas, Jayanthi Lea, Bo Li
De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. Science translational medicine 12 (557) (2021)
Huihui Zhang, Fanlin Li, Jiang Cao, Xin Wang, Hai Cheng, Kunming Qi, Gang Wang, Kailin Xu, Junnian Zheng, Yang-Xin Fu, Xuanming Yang
A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity. Science translational medicine 13 (578) (2021)
Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, Myung-Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nicholas Borcherding, Daniel Koppel, Yang-Xin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nature communications 12 (1) (2021)
Lang Rao, Lei Wu, Zhida Liu, Rui Tian, Guocan Yu, Zijian Zhou, Kuikun Yang, Hong-Gang Xiong, Anli Zhang, Guang-Tao Yu, Wenjing Sun, Han Xu, Jingya Guo, Andrew Li, Hongmin Chen, Zhi-Jun Sun, Yang-Xin Fu, Xiaoyuan Shawn Chen
Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. Nature communications 11 (1) (2020)
Chuanhui Han, Zhida Liu, Yunjia Zhang, Aijun Shen, Chunbo Dong, Anli Zhang, Casey Timmerman, Zhenhua Ren, Changzheng Lu, Xuezhi Cao, Chun-Li Zhang, Jian Qiao, Yang-Xin Fu
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nature immunology 21 (5) (2020)
Qi Peng, Xiangyan Qiu, Zihan Zhang, Silin Zhang, Yuanyuan Zhang, Yong Liang, Jingya Guo, Hua Peng, Mingyi Chen, Yang-Xin Fu, Haidong Tang
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nature communications 11 (1) (2020)
Wenjun Wang, Xiaoxiao Zhou, Yingjie Bian, Shan Wang, Qian Chai, Zhenqian Guo, Zhenni Wang, Ping Zhu, Hua Peng, Xiyun Yan, Wenhui Li, Yang-Xin Fu, Mingzhao Zhu
Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nature nanotechnology 15 (5) (2020)
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
Author Correction: A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature communications 11 (1) (2020)
Chuanhui Han, Anli Zhang, Zhida Liu, Casey Moore, Yang-Xin Fu
Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy. Oncogene 40 (5) (2020)
Hao Zuo, Dengbao Yang, Qiwen Yang, Haidong Tang, Yang-Xin Fu, Yihong Wan
Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nature communications 11 (1) (2020)
Zhida Liu, Chuanhui Han, Chunbo Dong, Aijun Shen, Eric J Hsu, Zhenhua Ren, Changzheng Lu, Longchao Liu, Anli Zhang, Casey Timmerman, Yang Pu, Yang Wang, Mingyi Chen, Jian Qiao, Yang-Xin Fu
Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science immunology 4 (38) (2020)
Jian Qiao, Yang-Xin Fu
Cytokines that target immune killer cells against tumors. Cellular & molecular immunology 17 (7) (2020)
Charles S Fermaintt, Kanae Sano, Zhida Liu, Nozomi Ishii, Junichi Seino, Nicole Dobbs, Tadashi Suzuki, Yang-Xin Fu, Mark A Lehrman, Ichiro Matsuo, Nan Yan
A bioactive mammalian disaccharide associated with autoimmunity activates STING-TBK1-dependent immune response. Nature communications 10 (1) (2019)
Ainhoa Arina, Michael Beckett, Christian Fernandez, Wenxin Zheng, Sean P Pitroda, Steven J Chmura, Jason J Luke, Martin Forde, Yuzhu Hou, Byron Burnette, Helena Mauceri, Israel Lowy, Tasha Sims, Nikolai Khodarev, Yang-Xin Fu, Ralph R Weichselbaum
Tumor-reprogrammed resident T cells resist radiation to control tumors. Nature communications 10 (1) (2019)
Xiaoguang Li, Zhida Liu, Anli Zhang, Chuanhui Han, Aijun Shen, Lingxiang Jiang, David A Boothman, Jian Qiao, Yang Wang, Xiumei Huang, Yang-Xin Fu
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nature communications 10 (1) (2019)
Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature communications 10 (1) (2019)
Yanyan Wang, Xingrong Du, Jun Wei, Lingyun Long, Haiyan Tan, Cliff Guy, Yogesh Dhungana, Chenxi Qian, Geoffrey Neale, Yang-Xin Fu, Jiyang Yu, Junmin Peng, Hongbo Chi
LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity. Cell research 29 (5) (2019)
Tae-Jin Kim, Gayoung Park, Jeongmin Kim, Seon Ah Lim, Jiyoung Kim, Kyungtaek Im, Min Hwa Shin, Yang-Xin Fu, Maria-Luisa Del Rio, Jose-Ignacio Rodriguez-Barbosa, Cassian Yee, Kyung-Suk Suh, Seong-Jin Kim, Sang-Jun Ha, Kyung-Mi Lee
CD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nature communications 10 (1) (2019)
Gui-Zhen Wang, Li Zhang, Xin-Chun Zhao, San-Hui Gao, Li-Wei Qu, Hong Yu, Wen-Feng Fang, Yong-Chun Zhou, Fan Liang, Chen Zhang, Yun-Chao Huang, Zhihua Liu, Yang-Xin Fu, Guang-Biao Zhou
The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nature communications 10 (1) (2019)
Mingye Feng, Wen Jiang, Yon Son Betty Kim, Cheng Cheng Zhang, Yang-Xin Fu, Irving L Weissman
Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature reviews. Cancer 19 (10) (2019)
Zhida Liu, Chuanhui Han, Yang-Xin Fu
Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular & molecular immunology 17 (1) (2019)
Kaiting Yang, Yong Liang, Zhichen Sun, Longchao Liu, Jing Liao, Hairong Xu, Mingzhao Zhu, Yang-Xin Fu, Hua Peng
T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. Scientific reports 8 (1) (2018)
Yong Liang, Haidong Tang, Jingya Guo, Xiangyan Qiu, Zecheng Yang, Zhenhua Ren, Zhichen Sun, Yingjie Bian, Lily Xu, Hairong Xu, Jiao Shen, Yanfei Han, Haidong Dong, Hua Peng, Yang-Xin Fu
Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nature communications 9 (1) (2018)
Kuangda Lu, Chunbai He, Nining Guo, Christina Chan, Kaiyuan Ni, Guangxu Lan, Haidong Tang, Charles Pelizzari, Yang-Xin Fu, Michael T Spiotto, Ralph R Weichselbaum, Wenbin Lin
Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. Nature biomedical engineering 2 (8) (2018)
Zhida Liu, Chang Zhou, Yan Qin, Zihao Wang, Luyao Wang, Xiuli Wei, Yinjian Zhou, Qicheng Li, Hang Zhou, Wenjun Wang, Yang-Xin Fu, Mingzhao Zhu, Wei Liang
Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine. Cell discovery 3 (2017)
Min Luo, Hua Wang, Zhaohui Wang, Haocheng Cai, Zhigang Lu, Yang Li, Mingjian Du, Gang Huang, Chensu Wang, Xiang Chen, Matthew R Porembka, Jayanthi Lea, Arthur E Frankel, Yang-Xin Fu, Zhijian J Chen, Jinming Gao
A STING-activating nanovaccine for cancer immunotherapy. Nature nanotechnology 12 (7) (2017)
Hua Liang, Liufu Deng, Yuzhu Hou, Xiangjiao Meng, Xiaona Huang, Enyu Rao, Wenxin Zheng, Helena Mauceri, Matthias Mack, Meng Xu, Yang-Xin Fu, Ralph R Weichselbaum
Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nature communications 8 (1) (2017)